Buy Rating for Corbus Pharmaceuticals’ CRB-701: Promising Efficacy and Safety in Oncology

Analyst Andres Y. Maldonado of H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), retaining the price target of $40.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the potential of Corbus Pharmaceuticals’ CRB-701 as a leading Nectin-4 ADC. The drug’s design, which includes a cleavable linker and optimized drug-to-antibody ratio, aims to maintain potency while reducing off-target toxicities, setting it apart from competitors.
CRB-701 has demonstrated promising efficacy in early trials, particularly in heavily pretreated head and neck squamous cell carcinoma, and has shown activity in urothelial and cervical cancers. The drug’s safety profile is notably cleaner than other ADCs, with fewer severe adverse events reported. Additionally, the FDA’s Fast Track designation for CRB-701 in metastatic cervical cancer underscores its clinical potential and regulatory alignment, further supporting the Buy rating.

In another report released on May 20, Mizuho Securities also maintained a Buy rating on the stock with a $32.00 price target.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRBP in relation to earlier this year.